InMed Pharmaceuticals

InMed Pharmaceuticals Current Assets

The Current Assets of InMed Pharmaceuticals (INM) as of Nov 3, 2026 is 12.87 M USD. In the previous year, Current Assets was 8.69 M USD — a change of 48.08% (higher).

Current Assets

12.87 MUSD

YoY

48.08%

Last updated:

Current Assets of InMed Pharmaceuticals is 2025 12.87 M USD. Current Assets of InMed Pharmaceuticals was 2024 8.69 M USD. It decreases by 48.08% higher compared to the previous year.

The InMed Pharmaceuticals Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
20.36 M USD
Jan 1, 2019
14.16 M USD
Jan 1, 2020
6.32 M USD
Jan 1, 2021
8.38 M USD
Jan 1, 2022
9.60 M USD
Jan 1, 2023
11.34 M USD
Jan 1, 2024
8.69 M USD
Jan 1, 2025
12.87 M USD
The InMed Pharmaceuticals Current Assets history
YEARCurrent AssetsYoY
12.87 MUSD+48.08%
8.69 MUSD-23.37%
11.34 MUSD+18.12%
9.60 MUSD+14.56%
8.38 MUSD+32.59%
6.32 MUSD-55.37%
14.16 MUSD-30.45%
20.36 MUSD+279.85%
5.36 MUSD+3,473.33%
150,000.00USD-25.00%
200,000.00USD+5.26%
190,000.00USD—
0.00USD-100.00%
40,000.00USD-84.00%
250,000.00USD+2,400.00%
10,000.00USD-50.00%
20,000.00USD-96.61%
590,000.00USD+59.46%
370,000.00USD-19.57%
460,000.00USD-25.81%
620,000.00USD+148.00%
250,000.00USD-39.02%
410,000.00USD-60.19%
1.03 MUSD-56.54%
2.37 MUSD+79.55%
1.32 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

InMed Pharmaceuticals Stock analysis

What does InMed Pharmaceuticals do? InMed Pharmaceuticals Inc is a biopharmaceutical company based in Vancouver, Canada, listed on the stock exchange in June 2001. The firm operates through two main segments: InMed Pharmaceuticals and BayMedica. The InMed segment focuses on the research and development of prescription-based cannabinoid products, specifically targeting diseases with high unmet medical needs. Key candidates include INM-755, a topical skin cream for Epidermolysis Bullosa, and INM-088 for glaucoma treatment. The BayMedica segment develops proprietary manufacturing technologies to produce rare cannabinoids for the health and wellness industry. The company leverages its expertise in rare cannabinoids and analogs to address significant therapeutic gaps. InMed Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InMed Pharmaceuticals stock

Current Assets of InMed Pharmaceuticals is 12.87 M USD in 2025.

Current Assets of InMed Pharmaceuticals changed from 8.69 M USD to 12.87 M USD, representing a 48.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets InMed Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's InMed Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — InMed Pharmaceuticals

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — InMed Pharmaceuticals